Literature DB >> 19844782

Beneficial effects of TLR-2/6 ligation in pulmonary bacterial infection and immunization with Pseudomonas aeruginosa.

Tanja Kerber-Momot1, Damaris Leemhuis, Anke Lührmann, Antje Munder, Burkhard Tümmler, Reinhard Pabst, Thomas Tschernig.   

Abstract

Pseudomonas aeruginosa (P. aeruginosa) is the major pathogen in nosocomial and life-threatening infections of immunocompromised or critically ill patients. The macrophage-activating lipopeptide-2 (MALP-2) activates the immune system via Toll-like receptors (TLR) 2 and 6 and leads to an accumulation of immune cells in lungs of young adult (8-10 week old) rats after intratracheal application. This is characterized by a high increase of granulocyte numbers in the BAL 24 h after MALP-2 treatment. It was hypothesized that MALP-2 may have a positive effect on the clinical course of an experimental infection. Therefore, rats were treated with MALP-2 at different time points following an infection with P. aeruginosa. The effect of MALP-2 in combination with immunization with inactivated P. aeruginosa was also investigated. Rats (n = 10) were infected intratracheally (i.t.) with 1 x 10(8) CFU P. aeruginosa on day 0. They were treated on day -3, -1, 0 and +1 with 2.5 microg MALP-2 or the vehicle i.t. In additional experiments, rats were immunized on day -21 and -14 with 1 x 10(8) CFU of inactivated P. aeruginosa bacteria and 2.5 microg MALP-2 or vehicle with 1 x 10(8) CFU of inactivated bacteria and isopropanol. The clinical score, rectal temperature and weight of the rats were checked in both treatment and immunization experiments twice a day. On day 2 they were sacrificed, CFU were determined in the left lung, the right lung being used for histology. In the group treated with MALP-2 1 day prior to infection significant effects were seen: The rectal temperature was about 2 degrees C higher in comparison to the controls at 6 h and also 1 day after infection. Both the symptoms of the infection and the weight loss were significantly reduced. In addition, the CFU and the inflammation in the lung tissue were significantly lower. These effects were not observed after treatment on day -3, 0 or +1. The MALP-2 enhanced immunization only resulted in a tendency to clinical improvement. In conclusion, local immunostimulation at the appropriate time can enhance the host defense against bacteria in the lung.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19844782     DOI: 10.1007/s10753-009-9158-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  18 in total

1.  Nosocomial lower respiratory tract infections: prevalence and risk factors in 14 Greek hospitals.

Authors:  D P Kofteridis; J A Papadakis; D Bouros; P Nikolaides; G Kioumis; S Levidiotou; E Maltezos; S Kastanakis; S Kartali; A Gikas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-12       Impact factor: 3.267

Review 2.  Experimental bronchial asthma - the strength of the species rat.

Authors:  Thomas Tschernig; Detlef Neumann; Andreas Pich; Martina Dorsch; Reinhard Pabst
Journal:  Curr Drug Targets       Date:  2008-06       Impact factor: 3.465

3.  Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice.

Authors:  U Deiters; P F Mühlradt
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

Review 4.  Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism.

Authors:  Matthias Trautmann; Philipp M Lepper; Mathias Haller
Journal:  Am J Infect Control       Date:  2005-06       Impact factor: 2.918

5.  Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung.

Authors:  Kiyoshi Shingu; Carsten Kruschinski; Anke Lührmann; Karsten Grote; Thomas Tschernig; Stephan Von Hörsten; Reinhard Pabst
Journal:  Am J Respir Cell Mol Biol       Date:  2003-03       Impact factor: 6.914

6.  Functional genomics of Pseudomonas aeruginosa to identify habitat-specific determinants of pathogenicity.

Authors:  Lutz Wiehlmann; Antje Munder; Thorsten Adams; Mario Juhas; Harald Kolmar; Prabhakar Salunkhe; Burkhard Tümmler
Journal:  Int J Med Microbiol       Date:  2007-05-04       Impact factor: 3.473

7.  Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia.

Authors:  Katrin Reppe; Thomas Tschernig; Anke Lührmann; Vincent van Laak; Karsten Grote; Maren V Zemlin; Birgitt Gutbier; Holger C Müller; Mischo Kursar; Hartwig Schütte; Simone Rosseau; Reinhard Pabst; Norbert Suttorp; Martin Witzenrath
Journal:  Am J Respir Cell Mol Biol       Date:  2008-10-17       Impact factor: 6.914

Review 8.  Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis.

Authors:  Marisa I Gómez; Alice Prince
Journal:  Curr Opin Pharmacol       Date:  2007-04-05       Impact factor: 5.547

9.  In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application.

Authors:  Anke Lührmann; Ursula Deiters; Julia Skokowa; Michaela Hanke; Johannes E Gessner; Peter F Mühlradt; Reinhard Pabst; Thomas Tschernig
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

View more
  8 in total

1.  Regulation on expression of toll-like receptors on monocytes after stimulation with the 3-o-C12-HSL molecule from Pseudomonas aeruginosa.

Authors:  Qi Lu; Yujia Lin; Xiqiang Yang; Wei Liu; Xianhong Zhang; Daochao Huang; Haiying Zhong
Journal:  Curr Microbiol       Date:  2012-06-27       Impact factor: 2.188

2.  Pulmonary immunostimulation with MALP-2 in influenza virus-infected mice increases survival after pneumococcal superinfection.

Authors:  Katrin Reppe; Peter Radünzel; Kristina Dietert; Thomas Tschernig; Thorsten Wolff; Sven Hammerschmidt; Achim D Gruber; Norbert Suttorp; Martin Witzenrath
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

3.  Inactivated pseudomonas aeruginosa protects against myocardial ischemia reperfusion injury via Nrf2 and HO-1.

Authors:  Zhigang Zhao; Zhongzhi Tang; Wenkai Zhang; Jie Liu; Bo Li; Shifang Ding
Journal:  Exp Ther Med       Date:  2020-03-17       Impact factor: 2.447

4.  Tacrolimus downregulates inflammation by regulating pro‑/anti‑inflammatory responses in LPS‑induced keratitis.

Authors:  Yifeng Yu; Jing Zhong; Lulu Peng; Bowen Wang; Saiqun Li; Haixiang Huang; Yuqing Deng; Henan Zhang; Ruhui Yang; Changyun Wang; Jin Yuan
Journal:  Mol Med Rep       Date:  2017-08-24       Impact factor: 2.952

5.  MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock.

Authors:  Roman Pfeifer; Thomas Tschernig; Philipp Lichte; Derek Dombroski; Philipp Kobbe; Hans-Christoph Pape
Journal:  J Inflamm (Lond)       Date:  2013-04-12       Impact factor: 4.981

6.  A purified recombinant lipopeptide as adjuvant for cancer immunotherapy.

Authors:  Ying-Chyi Song; Hsueh-Hung Liu; I-Hua Chen; Hsin-Wei Chen; Pele Chong; Chih-Hsiang Leng; Shih-Jen Liu
Journal:  Biomed Res Int       Date:  2014-03-11       Impact factor: 3.411

7.  Pseudomonas aeruginosa LasB Subverts Alveolar Macrophage Activity by Interfering With Bacterial Killing Through Downregulation of Innate Immune Defense, Reactive Oxygen Species Generation, and Complement Activation.

Authors:  Fabien Bastaert; Saadé Kheir; Vinciane Saint-Criq; Bérengère Villeret; Pham My-Chan Dang; Jamel El-Benna; Jean-Claude Sirard; Romé Voulhoux; Jean-Michel Sallenave
Journal:  Front Immunol       Date:  2018-07-23       Impact factor: 7.561

8.  Streptococcus pneumoniae PepO promotes host anti-infection defense via autophagy in a Toll-like receptor 2/4 dependent manner.

Authors:  Zhaoche Shu; Jun Yuan; Hong Wang; Jinghui Zhang; Sijie Li; Hong Zhang; Yusi Liu; Yibing Yin; Xuemei Zhang
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.